80 related articles for article (PubMed ID: 20500028)
1. Clinical heterogeneity and tumor control probability.
Eisbruch A
Acta Oncol; 2010 Nov; 49(8):1385-7. PubMed ID: 20500028
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus and oral cancer: looking toward the clinic.
McNeil C
J Natl Cancer Inst; 2008 Jun; 100(12):840-2. PubMed ID: 18544734
[No Abstract] [Full Text] [Related]
3. StatBite: Proportion of specific cancers caused by HPV.
J Natl Cancer Inst; 2010 Jun; 102(12):839. PubMed ID: 20530763
[No Abstract] [Full Text] [Related]
4. Individualizing therapy for oropharyngeal cancer patients.
Demiroz C; Eisbruch A
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1181-4. PubMed ID: 19761420
[No Abstract] [Full Text] [Related]
5. StatBite. Oropharyngeal cancers are an increasing proportion of all head and neck cancers.
J Natl Cancer Inst; 2010 Oct; 102(19):1457. PubMed ID: 20870976
[No Abstract] [Full Text] [Related]
6. TCP and NTCP in preclinical and clinical research in Europe.
Baumann M; Petersen C; Krause M
Rays; 2005; 30(2):121-6. PubMed ID: 16294904
[TBL] [Abstract][Full Text] [Related]
7. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs.
Verbakel WF; Senan S; Cuijpers JP; Slotman BJ; Lagerwaard FJ
Radiother Oncol; 2009 Oct; 93(1):122-4. PubMed ID: 19552979
[TBL] [Abstract][Full Text] [Related]
8. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.
Keall PJ; Webb S
Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142
[TBL] [Abstract][Full Text] [Related]
9. HPV-induced oropharyngeal cancer, immune response and response to therapy.
Vu HL; Sikora AG; Fu S; Kao J
Cancer Lett; 2010 Feb; 288(2):149-55. PubMed ID: 19628331
[TBL] [Abstract][Full Text] [Related]
10. HPV-positive oropharyngeal cancer: data may justify new approach.
Peres J
J Natl Cancer Inst; 2010 Oct; 102(19):1456-9. PubMed ID: 20870975
[No Abstract] [Full Text] [Related]
11. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia.
Søvik A; Malinen E; Skogmo HK; Bentzen SM; Bruland OS; Olsen DR
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1496-504. PubMed ID: 17674980
[TBL] [Abstract][Full Text] [Related]
12. Spinal cord planning risk volumes for intensity-modulated radiation therapy of head-and-neck cancer.
Breen SL; Craig T; Bayley A; O'Sullivan B; Kim J; Jaffray D
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):321-5. PubMed ID: 16377418
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
14. EUCLID: an outcome analysis tool for high-dimensional clinical studies.
Gayou O; Parda DS; Miften M
Phys Med Biol; 2007 Mar; 52(6):1705-19. PubMed ID: 17327657
[TBL] [Abstract][Full Text] [Related]
15. Intensity modulated radiation therapy for oropharyngeal cancer: the sensitivity of plan objectives and constraints to set-up uncertainty.
Ploquin N; Song W; Lau H; Dunscombe P
Phys Med Biol; 2005 Aug; 50(15):3515-33. PubMed ID: 16030380
[TBL] [Abstract][Full Text] [Related]
16. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
18. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
Grégoire V
Rays; 2005; 30(2):105-8. PubMed ID: 16294902
[TBL] [Abstract][Full Text] [Related]
19. From cell population models to tumor control probability: including cell cycle effects.
Hillen T; de Vries G; Gong J; Finlay C
Acta Oncol; 2010 Nov; 49(8):1315-23. PubMed ID: 20843174
[TBL] [Abstract][Full Text] [Related]
20. CancerScope: Patients with HPV-linked throat cancer fare better than others.
Printz C
Cancer; 2009 Nov; 115(22):5131. PubMed ID: 19890875
[No Abstract] [Full Text] [Related]
[Next] [New Search]
